BACKGROUND: Concomitant tricuspid valve repair (TVR) and double lung transplantation (DLTx) has been a surgical option at our institution since 2004 in an attempt to improve the outcome of DLTx for end-stage pulmonary hypertension, severe tricuspid regurgitation, and right ventricle (RV) dysfunction. This study is a review of that single institutional experience. METHODS: Consecutive cases of concomitant TVR and DLTx performed between 2004 and 2009 (TVR group, n = 20) were retrospectively compared with cases of DLTx alone for severe pulmonary hypertension without TVR (non-TVR group, n = 58). RESULTS: There was one in-hospital death in the TVR group. The 90-day and 1- and 3-year survival rates for the TVR group were 90%, 75%, and 65%, respectively, which were not significantly different from those for the non-TVR group. The TVR group required less inotropic support and less prolonged mechanical ventilation in the ICU. Follow-up echocardiography demonstrated immediate elimination of both volume and pressure overload in the RV and tricuspid regurgitation in the TVR group. Notably, there was a significantly lower incidence of primary graft dysfunction following transplantation in the TVR group (P < .05). Pulmonary functional improvement shown by an FEV(1) increase after 6 months was also significantly better in the TVR group (40% vs 20%, P < .05). CONCLUSIONS: Combined TVR and DLTx procedures were successfully performed without an increase in morbidity or mortality and contributed to decreased primary graft dysfunction. In our experience, this combined operative approach achieves clinical outcomes equal or superior to the outcomes seen in DLTx patients without RV dysfunction and severe tricuspid regurgitation.
BACKGROUND: Concomitant tricuspid valve repair (TVR) and double lung transplantation (DLTx) has been a surgical option at our institution since 2004 in an attempt to improve the outcome of DLTx for end-stage pulmonary hypertension, severe tricuspid regurgitation, and right ventricle (RV) dysfunction. This study is a review of that single institutional experience. METHODS: Consecutive cases of concomitant TVR and DLTx performed between 2004 and 2009 (TVR group, n = 20) were retrospectively compared with cases of DLTx alone for severe pulmonary hypertension without TVR (non-TVR group, n = 58). RESULTS: There was one in-hospital death in the TVR group. The 90-day and 1- and 3-year survival rates for the TVR group were 90%, 75%, and 65%, respectively, which were not significantly different from those for the non-TVR group. The TVR group required less inotropic support and less prolonged mechanical ventilation in the ICU. Follow-up echocardiography demonstrated immediate elimination of both volume and pressure overload in the RV and tricuspid regurgitation in the TVR group. Notably, there was a significantly lower incidence of primary graft dysfunction following transplantation in the TVR group (P < .05). Pulmonary functional improvement shown by an FEV(1) increase after 6 months was also significantly better in the TVR group (40% vs 20%, P < .05). CONCLUSIONS: Combined TVR and DLTx procedures were successfully performed without an increase in morbidity or mortality and contributed to decreased primary graft dysfunction. In our experience, this combined operative approach achieves clinical outcomes equal or superior to the outcomes seen in DLTx patients without RV dysfunction and severe tricuspid regurgitation.
Authors: Alan L Hinderliter; Park W Willis; Walker A Long; William R Clarke; David Ralph; Edgar J Caldwell; William Williams; Neil A Ettinger; Nicholas S Hill; Warren R Summer; Bennett de Boisblanc; Gary Koch; Shu Li; Linda M Clayton; Maria M Jöbsis; James W Crow Journal: Am J Cardiol Date: 2003-04-15 Impact factor: 2.778
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Jason D Christie; Martin Carby; Remzi Bag; Paul Corris; Marshall Hertz; David Weill Journal: J Heart Lung Transplant Date: 2005-06-04 Impact factor: 10.247
Authors: Rajeev Saggar; Joseph P Lynch; John A Belperio; S Samuel Weigt; Ariss Derhovanessian; Sachin Gupta; Rajan Saggar Journal: Semin Respir Crit Care Med Date: 2010-03-30 Impact factor: 3.119
Authors: Jason D Christie; Leah B Edwards; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; David O Taylor; Anna Y Kucheryavaya; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2009-10 Impact factor: 10.247
Authors: J S Gammie; R J Keenan; S M Pham; M F McGrath; B G Hattler; E Khoshbin; B P Griffith Journal: J Thorac Cardiovasc Surg Date: 1998-02 Impact factor: 5.209
Authors: J F Rhodes; A D Blaufox; H S Seiden; J D Asnes; R P Gross; J P Rhodes; R B Griepp; A F Rossi Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Scott B Johnson; Anna M Allred; Adam M Cline; Luis F Angel; Edward Y Sako; Clinton E Baisden; John H Calhoon Journal: Ann Thorac Surg Date: 2006-08 Impact factor: 4.330
Authors: K Bando; J M Armitage; I L Paradis; R J Keenan; R L Hardesty; H Konishi; K Komatsu; K L Stein; A N Shah; H T Bahnson Journal: J Thorac Cardiovasc Surg Date: 1994-12 Impact factor: 5.209